(NASDAQ: EYPT) Eyepoint Pharmaceuticals's forecast annual revenue growth rate of -7.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Eyepoint Pharmaceuticals's revenue in 2025 is $45,713,000.On average, 4 Wall Street analysts forecast EYPT's revenue for 2025 to be $901,391,366, with the lowest EYPT revenue forecast at $265,496,511, and the highest EYPT revenue forecast at $1,627,104,579. On average, 2 Wall Street analysts forecast EYPT's revenue for 2026 to be $262,425,214, with the lowest EYPT revenue forecast at $259,353,918, and the highest EYPT revenue forecast at $265,496,511.
In 2027, EYPT is forecast to generate $3,678,730,571 in revenue, with the lowest revenue forecast at $3,678,730,571 and the highest revenue forecast at $3,678,730,571.